SCHEMBL1477031

SCHEMBL1477031

Clc1cccc(C#Cc2cccnc2)c1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.50
CYP2A6 P11509 5/20 0.50
KCNH2 Q12809 1/20 0.50
PTGDR2 Q9Y5Y4 1/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2D6 P10635 3/20 0.49
CYP2E1 P05181 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP19A1 P11511 1/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C8 P10632 1/20 0.47
CHRNB2 P17787 3/20 0.46
CHRNA4 P43681 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30669242 1.00 GRM5 (0.50) GRM5CYP2A6KCNH2PTGDR2CYP2C9
Hydrochloric Acid SCHEMBL1478818 0.98 CYP2A6 (0.50) GRM5CYP2A6KCNH2PTGDR2CYP2C9
SCHEMBL13731781 0.85 CYP2A6 (0.50) GRM5CYP2A6PTGDR2CYP2C9CYP2B6
SCHEMBL13732174 0.83 GRM5 (0.62) GRM5KCNH2CHRNB2CHRNA4
SCHEMBL30707869 0.82 KCNH2 (0.67) GRM5KCNH2PTGDR2CYP2C9CYP2D6
SCHEMBL4562631 0.82 KCNH2 (0.67) GRM5KCNH2PTGDR2CYP2C9CYP2D6
SCHEMBL3796332 0.82 CYP2A6 (0.67) GRM5CYP2A6CYP2C9CYP2B6CYP2C19
SCHEMBL3837868 0.81 CYP2A6 (0.53) GRM5CYP2A6PTGDR2CYP2C9CYP2B6
SCHEMBL2201051 0.80 PKM (0.51) GRM5PTGDR2CYP2D6CYP3A4CYP1A2
SCHEMBL4862438 0.80 NPY5R (0.46) GRM5CYP2A6PTGDR2CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US disclosed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP disclosed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US disclosed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP disclosed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 GRM5 48/4885CYP2A6 1624/4885KCNH2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.